Peer-reviewedCC0Morbidity and Mortality Weekly Report
Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025
- 1Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, CDC; U.S. Public Health Service, Rockville, Maryland.
Related
- Hope, hype, and high costs: Navigating glucagon-like Peptide-1 based therapy initiation among young adults
- Association of Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors with Tuberculosis and Mortality in Adults with Diabetes
- De-escalating Therapy in Obstructive Sleep Apnoea After Glucagon-Like Peptide-1 Receptor Agonist-Induced Weight Loss: A Narrative Review
- Glucagon-like peptide-1 receptor agonists beyond weight loss: A paradigm shift in cardiovascular prevention
- Glucagon-like peptide-1 secretagogues from the leaves of Oparanthus teikiteetinii
BibTeX
@article{pierce2026glucagonlike,
title = {{Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025}},
author = {Samantha L. Pierce and Lilanthi Balasuriya and Lyudmyla Kompaniyets and Alyson B. Goodman},
journal = {Morbidity and Mortality Weekly Report},
year = {2026},
month = nov,
doi = {10.15585/mmwr.mm7544a1},
url = {https://doi.org/10.15585/mmwr.mm7544a1},
note = {CC0},
}
RIS
TY - JOUR
TI - Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025
AU - Samantha L. Pierce
AU - Lilanthi Balasuriya
AU - Lyudmyla Kompaniyets
AU - Alyson B. Goodman
PY - 2026
DA - 2026/11/12
JO - Morbidity and Mortality Weekly Report
DO - 10.15585/mmwr.mm7544a1
UR - https://doi.org/10.15585/mmwr.mm7544a1
SN - 0149-2195
SN - 1545-861X
ER -